ACET - Adicet Bio Inc

ACET - Adicet Bio Inc

https://www.adicetbio.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Adicet Bio ( ACET ) Upgraded to Buy: Here's Why

Zacks Commentary • 1 month ago • score: 0.38

Adicet Bio (ACET) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Adicet Bio ( ACET ) Q2 Loss Widens 3%

Motley Fool • 1 month, 1 week ago • score: 0.12

Adicet Bio ( NASDAQ:ACET ) , a biotechnology company focused on gamma delta T cell therapies for autoimmune diseases and cancer, reported its second quarter 2025 earnings on August 7, 2025. No revenue was recognized as the company remains a precommercial stage biotech.

Adicet Bio ( ACET ) Upgraded to Buy: Here's What You Should Know

Zacks Commentary • 4 months ago • score: 0.33

Adicet Bio (ACET) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday - Novartis ( NYSE:NVS )

Benzinga • 1 year ago • score: -0.06

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. HC Wainwright & Co. analyst Edward White downgraded the rating for Adicet Bio, Inc. ACET from Buy to ...

Adicet Bio ( NASDAQ:ACET ) Stock Rating Upgraded by StockNews.com

Stocknews.com • 1 year, 3 months ago • score: 0.42

StockNews.com upgraded shares of Adicet Bio ( NASDAQ:ACET - Free Report ) to a sell rating in a report published on Monday. A number of other analysts also recently commented on ACET. HC Wainwright reissued a buy rating and issued a $10.00 price objective on shares of Adicet Bio in a research ...

Why Adicet Bio ( ACET ) Stock Might be a Great Pick

Zacks Commentary • 1 year, 5 months ago • score: 0.73

Adicet Bio (ACET) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company is headquartered in Boston, Massachusetts.

52W High

$1.61

52W Low

$0.45

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.61

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-1.21

EV/Revenue (<3 favorable)

2.14

P/S (TTM) (<3 favorable)

9.72

P/B (<3 favorable)

0.50

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

2.79%

Institutions (25–75% balanced)

61.26%

Shares Outstanding

83,254,000

Float

61,917,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

24,990,000

EPS (TTM)

-1.30

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.64%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-1.00

Momentum

Bearish momentum

Value

0.0395

Previous

0.0387

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025